MapLight Therapeutics (MPLT) Reports $463.4M Cash and 2027–2028 Trial Readouts

MapLight Therapeutics reported $463.4M in cash and equivalents, sufficient for operations through 2028. The company expects topline results for VISTA in H2 2027 and ZEPHYR-2 in 2028, following positive ZEPHYR study results.

Original reporting
Published Nov 16, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MapLight Therapeutics (MPLT) Reports $463.4M Cash and 2027–2028 Trial Readouts — source image
Decision brief

The 30-second read

$MPLTNeutralMed
01

Why it matters

The cash runway reduces short-term financing concerns, but the stock's trajectory will hinge on the outcomes of the VISTA and ZEPHYR-2 trials.

02

Market read

Provides investors with fresh data on liquidity and upcoming clinical milestones, informing positioning ahead of potential trial-driven moves.

03

What to watch

Potential dilution if cash depletes before readouts; competitive landscape for VISTA and ZEPHYR-2 therapies.

Relevance 7/10Novelty 7/10Timing: ahead of H2 2027 trial readout

Background

MapLight Therapeutics is a clinical-stage biotech focusing on novel therapies. The disclosed cash balance and timeline for trial readouts are critical for assessing financial health and upcoming catalysts.

Company-level read

Ticker impact

$MPLTNeutralHigh confidence
Context

MapLight Therapeutics disclosed $463.4M cash runway through 2028 and upcoming trial readouts for VISTA (H2 2027) and ZEPHYR-2 (2028).

Expected impact

possible modest upside as investors price in runway and upcoming data, but limited immediate catalyst.

Evidence & confidence

Large cash balance is material for a clinical-stage biotech; upcoming readouts are key catalysts that can move the stock.

Market effects

Signals continued funding capacity for biotech firms developing late-stage therapies, may encourage sector investors.

Primarily U.S. biotech investors; limited broader market effect.

Limited to biotech/clinical trial community.

Counterpoint

Cash runway may mask underlying execution risk; without near-term data, stock could remain stagnant.

Key entities

  • MapLight Therapeutics

    Clinical-stage biotech reporting cash position and trial timelines.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and